Keytruda's initial fda approved use which cancer?

Which cancer was Keytruda (pembrolizumab) first approved by the FDA for?

Keytruda’s initial FDA approval was for melanoma—specifically unresectable or metastatic melanoma—in 2014. [1]

What stage or patient population did that first approval cover?

That first approval covered people with unresectable or metastatic melanoma, aligning with how early pembrolizumab use was positioned in advanced melanoma. [1]

Are there earlier approvals before melanoma?

No. The first FDA approval tied Keytruda to advanced melanoma (unresectable or metastatic) before later indications expanded into other cancers. [1]

Sources
[1] https://www.drugpatentwatch.com/